This vector can deliver multiple antigens into the MHC class I and II antigen presentation pathways to stimulate potent CD4+ and CD8+ T cell responses [14], and can break immunological tolerance to tumor antigens in transgenic mouse models [15]. Here, CD8A is linked to neoplasm.